Scope and Claims Dissection for US Patent 7,919,598 (Crystalline (S)-Propylene Glycol Solvate Form SC-3) and the US Patent Landscape Impacting Generic or Substitute Solvate Risk
US Patent 7,919,598 claims a narrow solid-state property set tied to a specific crystalline (S)-propylene glycol solvate designated compound Ia, form SC-3, plus dependent refinements based on unit cell parameters, XRPD peak positions, 13C NMR peak positions, DSC/DTA/heat events, TGA weight loss, and at least three synthetic routes that generate the same solvate (including seeded crystallization and specific reagent classes such as alkylsilyl hydrides and Lewis acids including BF3OEt2 and BF3·2CH3COOH). The patent’s US enforceable value is driven by (i) whether competitors can make the same solvate by alternative chemistry and (ii) whether they can demonstrate that their material is a different solvate form that avoids infringement tests tied to XRPD/NMR/unit-cell metrics.
The independent claim 1 is a product-by-structure/identity claim to a crystalline (S)-PG solvate of compound Ia with a form designation SC-3. The dependent claims 2 to 7 narrow identity further with room-temperature crystallography and spectroscopic/thermal fingerprints. Claims 8 to 15 add process claims that cover making the SC-3 solvate via treating specific upstream “compound A/B/If” intermediates with base/reducers and (S)-propylene glycol, including optional seeding and specific reduction activation conditions.
US Patent 7,919,598 Claims: What is actually protected by SC-3 (S)-propylene glycol solvate?
Short answer: The patent protects making, using, selling, or importing the crystalline (S)-PG solvate compound Ia form SC-3 in the US, and it also protects certain processes for preparing that solvate where intermediates and reaction conditions are within the claimed frameworks.
Claim 1: Is the core protection “crystalline (S)-PG solvate form SC-3”?
Claim 1 states:
- “A crystalline (S)-propylene glycol ((S)-PG) solvate compound Ia (form SC-3)”
This is the most legally significant scope anchor because it:
- Does not require a particular XRPD peak list, DSC event, or unit cell metrics in the claim text of 1.
- Relies on the form designation SC-3, which in practice functions like an identity definition that can be proven by the spec’s characterization methods (and by infringement testing in litigation).
Practical infringement risk: If a competitor’s solid matches SC-3 as defined by the intrinsic solid-state identity, claim 1 is the direct hit even if their process differs.
Claims 2–7: How do the dependent claims constrain “SC-3” identity?
These dependent claims convert “form SC-3” into a measurable fingerprint set that is typically used in disputes over polymorph/solvate infringement.
Claim 2: Room-temperature unit cell + space group + fractional coordinates
Claim 2 requires:
- Unit cell parameters substantially equal to:
- a = 11.2688(8) Å
- b = 4.8093(3) Å
- c = 46.723(3) Å
- α = β = γ = 90°
- Space group = P212121
- Molecules/asymmetric unit = 1
- Room temperature measurement
- Fractional atomic coordinates substantially as listed in Table 4
Legal effect: This claim limits the “form SC-3” definition to a crystallographic identity that is hard to fake without producing the same lattice.
Claim 4: XRPD peaks (2θ ± 0.1)
Claim 4 lists XRPD peaks at:
- 3.8, 7.6, 8.1, 8.7, 15.2, 15.7, 17.1, 18.9, 20.1 (each with ±0.1 tolerance)
Legal effect: This introduces a clear infringement testing criterion. However, infringement in practice often turns on:
- Whether a defendant’s pattern matches within tolerances.
- Whether impurities/mixture with other forms change the observable peak positions.
- Whether “substantially” allows for minor deviations.
Claim 5: 13C NMR peak positions
Claim 5 requires substantially similar peaks at:
- 16.2, 17.6, 39.3, 60.9, 63.3, 69.8, 76.9, 78.7, 79.4, 113.8, 123.6, 129.3, 130.5, 132.0, 135.7, 139.1, 158.0 ppm
Legal effect: This adds a second orthogonal identity test. While NMR can be sensitive to sample prep and solvent/hydrogen-bonding, peak-position matching provides additional proof of the same solid-state environment.
Claim 6: DSC endotherm 50–78°C (or FIG. 7)
Claim 6 requires:
- Endotherm in ~50°C to ~78°C (or as shown in the figure)
Claim 7: TGA weight loss ~18.7% to 240°C
Claim 7 requires:
- ~18.7% weight loss from room temperature to about 240°C
Legal effect: These thermal fingerprints help separate solvate vs anhydrate vs different hydrates/solvates. Thermal degradation overlap is a typical litigation battleground, but the combination with XRPD and unit cell reduces escape paths.
Claim 3: “substantially pure form”
Claim 3 requires:
- SC-3 in substantially pure form
Legal effect: Competitors may argue they only sell a mixture where SC-3 is not “substantially pure,” aiming to avoid claim 3. But claim 1 already covers “crystalline (S)-PG solvate compound Ia (form SC-3)” without an explicit purity limiter. Whether claim 3 matters depends on whether SC-3 is present as the dominant form and on how “substantially pure” is interpreted.
What processes are protected to make SC-3? (claims 8–15)
Short answer: The patent also claims preparation routes where the key structural event is introducing (S)-propylene glycol during crystallization/formation, often with base, optional seeding, and with specific reduction/activation chemistries for upstream intermediates.
Claim 8: treating compound A with base + (S)-propylene glycol
Claim 8 covers:
- Treating “compound A” in an organic solvent with base and (S)-propylene glycol
- Optional addition of seeds of SC-3
- Producing SC-3
This is a classic solvate-form crystallization claim that is difficult to avoid if the defendant uses the same intermediate and drives crystallization with (S)-PG in the presence of base.
Claims 9–10: seeding is explicitly called out
- Claim 9: repeats the optional-seeds requirement as a limitation.
- Claim 10: broader process involving:
- Treating compound B with a reducing agent in the presence of an activating group to provide compound I
- Then treating compound I with (S)-propylene glycol
- Optional seeding
- Organic solvent crystallization to provide SC-3
Claims 11–12: reduction reagent classes
Claim 11 defines:
- Reducing agent: alkylsilyl hydride
- Activating group: Lewis acid
Claim 12 specifies:
- Reducing agent: triethylsilane
- Activating group: BF3OEt2 or BF3·2CH3COOH
These are actionable because they map to common synthetic toolkits. A defendant trying to avoid claim coverage would need to use a substantially different reduction activation strategy, or argue their upstream intermediate set doesn’t fall into “compound B” → “compound I” as claimed.
Claims 13–15: multi-step route via acetic anhydride, DMAP, CH3CN
Claim 13 is the most complex:
- Treat compound If with acetic anhydride in presence of dimethylaminopyridine (DMAP) and CH3CN to form compound B′
- Then:
- Treat B′ with a reducing agent in presence of an activating group and CH3CN to form intermediate A
- Treat intermediate A with base, then with (S)-propylene glycol
- Optional seeding
- Organic solvent to form SC-3
Claims 14 and 15 define the reduction/activation reagent sets:
- Claim 14: alkylsilyl hydride + Lewis acid
- Claim 15: triethylsilane + BF3OEt2 or BF3·2CH3COOH
Process-claim takeaway: These claims are not just “make SC-3.” They are “make SC-3 using specific upstream chemistry and crystallization drivers,” which narrows infringement compared to a pure “any method producing SC-3” product claim.
How strong is infringement risk under US practice for solvate-form patents?
Short answer: Risk is high for any product that matches the SC-3 crystalline identity tests, because claim 1 covers the product without requiring the dependent fingerprints. Process claims provide additional coverage, particularly if a defendant uses the same intermediate set and reduction/activation conditions.
Most likely infringement scenarios
- Same solvate, different process: If a generic or competitor isolates and sells the same SC-3 form, claim 1 is the primary exposure regardless of how they made it.
- Same process, different final material: If they make SC-3 during manufacture but later transform it (or convert to another form), disputes become fact-intensive around final marketed solid-state form and timing.
- Mixture or partial conversion: “Substantially pure” appears in claim 3, but claim 1 still targets “crystalline … solvate … (form SC-3).” A defendant would focus on showing their marketed form is not SC-3.
Non-infringement strategy likely used by challengers
- Demonstrate that the marketed material is a different solvate/hydrate/polymorph with distinct XRPD peaks and/or different unit cell parameters.
- Use alternative crystallization conditions that lead away from SC-3.
- Avoid optional seeding if relevant to the process claims, and vary reduction chemistry outside alkylsilyl hydride/Lewis acid paradigms.
Where does US Patent 7,919,598 sit in the broader patent estate for crystalline solvate forms?
Short answer: Within typical small-molecule portfolios, this type of patent is usually part of a cluster: (i) API compound patents, (ii) salt/solvate polymorph patents, (iii) formulation/process patents.
However, without the patent’s title, assignee, publication family, priority, and related patents, a complete US landscape map (other patents in the same family, related continuations, and Orange Book listings tied to a specific NDA/ANDA) cannot be built from the claim text alone.
Actionable scope-based estate implications:
- If the API is protected by composition-of-matter claims, 7,919,598 can act as a secondary barrier by blocking specific solid-state alternatives that might otherwise be used to design around.
- If primary API patents have expired, solvate patents like this still restrict ANDA entry if the applicant chooses (or is forced) to use the same SC-3 form or if the claimed solvate is embedded in the formulation strategy.
What generic entry risks exist if a competitor tries to commercialize the same API?
Short answer: The risk is highest when the competitor’s candidate solid-state form inadvertently matches SC-3, or when their process and crystallization conditions are similar enough to yield SC-3 as the dominant solid.
Risk drivers
- Use of (S)-propylene glycol as a crystallization medium or solvating agent.
- Crystallization in an organic solvent with base, with or without seeding.
- Use of reduction routes employing alkylsilyl hydrides plus Lewis acid activation (triethylsilane + BF3OEt2 or BF3·2CH3COOH are explicitly claimed).
What to check in a competitor’s dossier
- XRPD peak list versus the claimed 2θ ± 0.1 set.
- Unit cell parameters and space group matching P212121.
- DSC/TGA signature consistency with claims 6 and 7.
- Whether their process includes the same reagent classes and intermediate transformation logic (compound A/B/If).
Key Takeaways
- Claim 1 is the core asset: it covers the crystalline (S)-propylene glycol solvate of compound Ia specifically defined as form SC-3.
- Dependent claims 2–7 lock down identity using unit cell crystallography, XRPD peak positions, 13C NMR peak positions, and thermal (DSC/TGA) fingerprints.
- Process claims 8–15 add manufacturing leverage: they protect multiple synthetic routes that culminate in SC-3, including optional seeding and reduction chemistry using alkylsilyl hydrides with Lewis acids (explicitly triethylsilane + BF3OEt2/BF3·2CH3COOH).
- Design-around depends on solid-state divergence: avoiding SC-3 requires producing a different solvate/polymorph with distinct crystallographic and spectral/thermal signatures, not just changing reagents.
FAQs
- How do XRPD peak tolerances affect infringement for SC-3 solvate patents?
- Does “form SC-3” operate like a polymorph definition or a claim-limiting identity criterion in practice?
- If a process temporarily forms SC-3 but converts to another form before sale, which claims are most relevant?
- Can substituting a different Lewis acid for BF3OEt2 avoid claims 11–12 and 15?
- What experimental confirmations most strongly distinguish one solvate from another when unit cell data are unavailable?
References (APA)
- US Patent 7,919,598. (Claims provided in prompt text).
